drugset / Trial / NCT07572383

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).

Timeline

Start
2026-05-14
Primary completion
2028-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject [68Ga]CBP8 Diagnostic / imaging agent 350 mbq Intravenous
Background Gadoterate meglumine Diagnostic / imaging agent 0.05 mmol Intravenous

Indications